» Articles » PMID: 37268741

Irritable Bowel Syndrome and Mental Health Comorbidity - Approach to Multidisciplinary Management

Overview
Specialty Gastroenterology
Date 2023 Jun 2
PMID 37268741
Authors
Affiliations
Soon will be listed here.
Abstract

Irritable bowel syndrome (IBS) affects 5-10% of the global population. Up to one-third of people with IBS also experience anxiety or depression. Gastrointestinal and psychological symptoms both drive health-care use in people with IBS, but psychological comorbidity seems to be more important for long-term quality of life. An integrated care approach that addresses gastrointestinal symptoms with nutrition and brain-gut behaviour therapies is considered the gold standard. However, best practice for the treatment of individuals with IBS who have a comorbid psychological condition is unclear. Given the rising prevalence of mental health disorders, discussion of the challenges of implementing therapy for people with IBS and anxiety and depression is critical. In this Review, we draw upon our expertise in gastroenterology, nutrition science and psychology to highlight common challenges that arise when managing patients with IBS and co-occurring anxiety and depression, and provide recommendations for tailoring clinical assessment and treatment. We provide best practice recommendations, including dietary and behavioural interventions that could be applied by non-specialists and clinicians working outside an integrated care model.

Citing Articles

Risk factors for developing irritable bowel syndrome: systematic umbrella review of reviews.

Sulaimi F, Ong T, Tang A, Quek J, Pillay R, Low D BMC Med. 2025; 23(1):103.

PMID: 39985070 PMC: 11846330. DOI: 10.1186/s12916-025-03930-5.


Anxiety and Depression Disorders in Vietnamese Patients With Irritable Bowel Syndrome: A Cross-Sectional Clinic-Based Study.

Phan T, Tran Q, Truong X, Nguyen T JGH Open. 2025; 9(2):e70116.

PMID: 39959452 PMC: 11825372. DOI: 10.1002/jgh3.70116.


Modifiable factors for irritable bowel syndrome: evidence from Mendelian randomisation approach.

Liu D, Cao M, Wu S, Jiang Y, Cao W, Lin T eGastroenterology. 2025; 3(1):e100126.

PMID: 39944930 PMC: 11770431. DOI: 10.1136/egastro-2024-100126.


Role of the gut microbiome in psychological symptoms associated with inflammatory bowel diseases.

Atanasova K, Knodler L, Reindl W, Ebert M, Thomann A Semin Immunopathol. 2025; 47(1):12.

PMID: 39870972 PMC: 11772462. DOI: 10.1007/s00281-025-01036-x.


Rome Foundation Working Team Report on overlap in disorders of gut-brain interaction.

Barbara G, Aziz I, Ballou S, Chang L, Ford A, Fukudo S Nat Rev Gastroenterol Hepatol. 2025; .

PMID: 39870943 DOI: 10.1038/s41575-024-01033-9.


References
1.
Chey W, Keefer L, Whelan K, Gibson P . Behavioral and Diet Therapies in Integrated Care for Patients With Irritable Bowel Syndrome. Gastroenterology. 2020; 160(1):47-62. DOI: 10.1053/j.gastro.2020.06.099. View

2.
Zamani M, Alizadeh-Tabari S, Zamani V . Systematic review with meta-analysis: the prevalence of anxiety and depression in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2019; 50(2):132-143. DOI: 10.1111/apt.15325. View

3.
Liu Q, He H, Yang J, Feng X, Zhao F, Lyu J . Changes in the global burden of depression from 1990 to 2017: Findings from the Global Burden of Disease study. J Psychiatr Res. 2019; 126:134-140. DOI: 10.1016/j.jpsychires.2019.08.002. View

4.
Black C, Ford A . Global burden of irritable bowel syndrome: trends, predictions and risk factors. Nat Rev Gastroenterol Hepatol. 2020; 17(8):473-486. DOI: 10.1038/s41575-020-0286-8. View

5.
Meringer H, Mehandru S . Gastrointestinal post-acute COVID-19 syndrome. Nat Rev Gastroenterol Hepatol. 2022; 19(6):345-346. PMC: 8981882. DOI: 10.1038/s41575-022-00611-z. View